Display options
Cite
Miyata Y, Mitsunari K, Akihiro A, et al. Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett. 2016;13(2):811-818doi: 10.3892/ol.2016.5484.
Miyata, Y., Mitsunari, K., Akihiro, A., Watanabe, S. I., Matsuo, T., Ohba, K., & Sakai, H. (2017). Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncology letters, 13(2), 811-818. https://doi.org/10.3892/ol.2016.5484
Miyata, Yasuyoshi, et al. "Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer." Oncology letters vol. 13,2 (2017): 811-818. doi: https://doi.org/10.3892/ol.2016.5484
Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H. Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12. PMID: 28356963; PMCID: PMC5351343.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12.

Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Oncology letters

Yasuyoshi Miyata, Kensuke Mitsunari, Asai Akihiro, Shin-Ichi Watanabe, Tomohiro Matsuo, Kojiro Ohba, Hideki Sakai

Affiliations

  1. Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.

PMID: 28356963 PMCID: PMC5351343 DOI: 10.3892/ol.2016.5484

Abstract

In patients with advanced urothelial cancer (UC), a combination of cisplatin (CDDP) and gemcitabine (GEM) is the most commonly used first-line systematic chemotherapy regimen. Although no standard regime for the treatment of CDDP-resistant UC has been established, GEM-based regimens are frequently used in these patients. In other types of cancer, human antigen R (HuR) status in cancer cells is closely associated with patient response to GEM. The aim of the present study was to establish the predictive potential of HuR expression for disease progression and survival in patients with UC who were treated with GEM-based regimens as a first or second-line chemotherapy. A total of 50 patients with advanced UC were enrolled in the current study. As first-line chemotherapy, methotrexate, vinblastine, epirubicin and CDDP (MVEC) combination therapy and GEM and CDDP combination therapy were administered in 34 (68.0%) and 16 patients (32.0%), respectively. Following progression, 45 patients (90.0%) were treated with combined GEM and paclitaxel therapy, and 5 patients (10.0%) were treated with GEM monotherapy. Cytoplasmic and nuclear HuR expression was evaluated using immunohistochemical techniques. The associations between HuR expression levels and local tumor response and treatment outcomes were analyzed. In first-line chemotherapy, no anticancer effects were observed to be significantly associated with nuclear or cytoplasmic HuR expression. In second-line chemotherapy nuclear HuR expression also exhibited no significant association with anticancer effects; however, the local tumor response was significantly improved if positive cytoplasmic HuR expression was present (P=0.002). Multivariate analyses revealed that cytoplasmic HuR expression levels were a significant predictive marker for longer OS (hazard ratio, 0.22; 95% confidence interval, 0.09-0.56; P=0.001). No significant association was observed between nuclear HuR expression levels and the overall survival. Therefore, cytoplasmic HuR expression is a significant predictive marker of response to GEM-based chemotherapy in patients with CDDP-resistant UC. Despite the limitations of a small and retrospective study, the results of the present study may facilitate the development of novel treatment strategies and provide a focus for additional basic and clinical studies.

Keywords: gemcitabine; human antigen R; predictive marker; urothelial cancer

References

  1. Mol Cancer. 2012 Mar 21;11:13 - PubMed
  2. PLoS One. 2010 Nov 29;5(11):e15455 - PubMed
  3. Transl Res. 2016 Sep;175:116-28 - PubMed
  4. PLoS One. 2013;8(3):e59095 - PubMed
  5. Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11 - PubMed
  6. Breast Cancer Res Treat. 2013 Sep;141(2):213-24 - PubMed
  7. Oncol Lett. 2013 Jul;6(1):156-160 - PubMed
  8. Anticancer Res. 2011 Jan;31(1):303-10 - PubMed
  9. Cancer Res Treat. 2009 Jun;41(2):87-92 - PubMed
  10. Anticancer Res. 2012 Aug;32(8):3211-8 - PubMed
  11. Cancer Res. 2009 Jun 1;69(11):4567-72 - PubMed
  12. Med Oncol. 2014 Sep;31(9):161 - PubMed
  13. BMC Cancer. 2013 Feb 08;13:72 - PubMed
  14. Tumour Biol. 2011 Jun;32(3):481-7 - PubMed
  15. J Clin Oncol. 1997 Jul;15(7):2564-9 - PubMed
  16. Cancer Res. 2014 Feb 15;74(4):1128-40 - PubMed
  17. Oncol Rep. 2014 Mar;31(3):1103-8 - PubMed
  18. Ann Surg. 2010 Sep;252(3):499-505; discussion 505-6 - PubMed
  19. Med Oncol. 2015 Oct;32(10):235 - PubMed
  20. Cancer Res. 1994 Aug 1;54(15):4138-43 - PubMed
  21. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  22. J Neurooncol. 2008 Jun;88(2):143-55 - PubMed
  23. Biochim Biophys Acta. 2016 Dec;1863(12 ):3125-3147 - PubMed
  24. Cancer Biol Ther. 2012 Aug;13(10):946-55 - PubMed
  25. Lancet. 2016 Dec 3;388(10061):2796-2810 - PubMed
  26. Expert Rev Anticancer Ther. 2009 Oct;9(10):1439-41 - PubMed
  27. Crit Rev Oncol Hematol. 2015 Oct;96(1):81-90 - PubMed
  28. Cancer Chemother Pharmacol. 2012 Sep;70(3):451-9 - PubMed
  29. J Clin Oncol. 2000 Sep;18(17):3068-77 - PubMed
  30. J Clin Oncol. 1997 Nov;15(11):3394-8 - PubMed
  31. BMB Rep. 2009 Mar 31;42(3):125-30 - PubMed
  32. Mol Clin Oncol. 2015 Mar;3(2):287-294 - PubMed
  33. J Clin Oncol. 2005 Jul 20;23(21):4602-8 - PubMed
  34. Cancer Res. 2010 Jul 15;70(14):5891-900 - PubMed
  35. J Urol. 1985 Mar;133(3):403-7 - PubMed
  36. Mol Cancer Ther. 2002 Apr;1(6):371-6 - PubMed
  37. Int J Mol Med. 2000 Feb;5(2):111-23 - PubMed
  38. Semin Oncol. 2007 Apr;34(2):135-44 - PubMed
  39. Cell Mol Life Sci. 2008 Oct;65(20):3168-81 - PubMed

Publication Types